CHAPTER 19: STAGE 3 NON-SMALL CELL LUNG CANCER

 

One website explains how stage 3 non-small cancer came to be subdivided into two categories:

Stage III lung cancer originally included patients with locally advanced disease, without distant metastasises. In 1986, the International Staging System for Lung Cancer further divided this group into two subgroups — IIIA and IIIB.4 These subgroups attempted to separate patients with tumors that were potentially resectable (stage IIIA) from patients with tumors clearly beyond the scope of surgical extirpation (stage IIIB). Stage IIIA originally included tumors of any size within the lung with limited extension of the primary site to the pericardium, mediastinal pleura or fat, or chest wall and without lymph node metastasises or with lymph node metastasises confined to the ipsilateral mediastinal lymph nodes. Experience has demonstrated that patients with this classification form a very heterogeneous group, with a long-term survival following surgical resection that ranges from 10 to 50%. Consequently,this classification has recently been modified. Chestnut (1)

One of the main difference between stage 3 A and B non small cancer is that surgery is part of 3A treatment. Surgery in stage 1 patients is designed to remove all of the tumor. In stage 3A while that may not be the goal, it is at least to remove enough tumor to make the risks of surgery and reduction of lung capacity make sense. In stage 3B where the tumor has extended beyond the immediate area into the mediastinum and adjoining structures, it is felt that the risk does not make sense. Since one group with different treatment plans is confusing, the division into 3A and 3B. Note that within each category are tumors with different characteristics, but the intra-category treatments are essentially the same.

19.2. CHEMOTHERAPY, RADIATION AND SURGERY ARE THE STANDARD TREATMENT WITH THE BEST MIX OF THE THREE STILL UNDER INVESTIGATION

A pharmaceutical site provides a good overview of Stage 3 A treatment:

"Historically, patients with stage III NSCLC (locally advanced disease) were managed with radiation therapy, but long-term survival was poor (5%–10%). The development of active chemotherapy regimens for NSCLC has led to the use of combined modality therapy for the management of stage III disease. Surgery and radiation are effective at controlling local disease, while chemotherapy works to control distant metastatic disease. Any two of these modalities or all three could be combined to treat stage III disease. However, patients with stage IIIb disease are generally not candidates for surgical resection and will most commonly receive combination chemotherapy, plus or minus radiation therapy.

Numerous trials comparing combined chemotherapy/radiation to radiation alone have been conducted in patients with stage III NSCLC. The chemotherapy regimens and radiation schedules have varied greatly among the studies, and conflicting results have emerged.... When two different meta-analyses were conducted with the data from all of the published randomized trials comparing chemotherapy/radiation with radiation alone, a small improvement in survival was reported for combined modality therapy. All of these studies utilized the older generation of chemotherapy regimens (cisplatin or cisplatin-based) in combination with radiotherapy. The improved activity of the newer combination chemotherapy regimens used in stage IV disease could lead to improved results when combined with radiation for the treatment of stage III disease. USPharmasist (2)

19.22 Chemotherapy Before Surgery or NeoAdjuvant Surgery

Chemotherapy and radiation are also, with research continuing as to what combination of these three forms of treatment will achieve the best results. Recall that Stage III A tumors involve either large T2 or 3 tumors or situations of significant lymph node involvement. Many physicians believe in chemotherapy before surgery:

Neoadjuvant chemotherapy with or without radiation therapy followed by surgery is another combined modality treatment for stage III (primarily stage IIIa) disease that is under investigation. Neoadjuvant chemotherapy is administered to patients with bulky disease prior to surgery in an attempt to decrease tumor size and increase surgical resectability. Two randomized studies have {favorably} compared chemotherapy followed by surgery with surgery alone." U.S. Pharmacist (2)

A recent article discusses the purposes of neoadjuvant chemotherapy:

The purpose of neoadjuvant chemotherapy is the eradication of micrometastatic disease, which is almost invariably manifest when ipsilateral mediastinal or subcarinal lymph nodes (N2) are involved. A chest computed tomography (CT) imaging study may show lymph nodes extending throughout many mediastinum regions, including the aortopulmonic window, the paratracheal region, and the precarinal and subcarinal areas.... Three randomized phase III trials reported that administering cisplatin-based chemotherapy before surgery to patients with resectable stage IIIA lung cancer improved survival results over those obtained with surgery alone or surgery plus radiotherapy

The MD Anderson investigators have recently updated the long-term follow-up of a selected high-risk population of patients with advanced but still resectable non-small cell lung cancer (NSCLC), T1-3N2M0 or T3-4N0M0.... This study shows that a preresectional chemotherapy regimen of cisplatin in combination with ifosfamide and mitomycin does improve the clinical outcome in comparison with surgery alone." Rosell (3)

19.4 STAGE IIIB NON-SMALL CELL LUNG CANCER

Chemotherapy is the primary treatment for Stage 3B and stage 3 non small cell lung cancer. We can note the following

     Chemotherapy is the primary treatment for Stage 3B and Stage 4 non small cell lung cancer.  We can note the following:

 

1.     In the 80's and early 90's, there was some debate about whether chemotherapy improved survival, and whether multiple agents helped.  That debate has probably ended.  Studies have demonstrated a consistent (if relatively modest) benefit to chemotherapy over other treatments, and have also shown that multi-modal chemotherapy is better than single agent.  If different drugs can fight cancer and work in different ways, it would make sense that a combination would achieve better results so long as significant side effects were not created.

2.     No one combination has demonstrated markedly better results throughout different clinical trials than others.  Clinical trials continue to test various combinations against one other to determine rates of  tumor diminution, partial and complete response rate (partial meaning at least 50% reduction of the tumor and complete meaning no visible tumor at a certain point in time), survival rates, and side effects.  To call such clinical trials Aexperimental@ is a little misleading.  The clinical trials are generally using the same drug combinations that practitioners use, only in a defined clinical setting.
 

3.     The term non-small cell lung cancer includes adenocarcinoma, squamous cell, and large cell cancers.  While we have grouped these three types together, it is possible that each type acts a little differently.  Conceivably, one drug could be better for squamous and another for large cell.  The fact that people with different types of tumors are grouped together, and different ages and health has made it more difficult to distinguish which drug is most effective.

4.     The platinum-drugs, cisplatin and carboplatin have been the mainstays of chemotherapy for stage 3B patients, with the above list concentrating on platinum drug combinations.  Taxol and Carboplatin appear in practice to be the most frequently used combination, though the literature does not clearly indicate better results with this combination.
 

5.     Gemcitabine and Gemcitabine combinations have been showing results almost comparable to these platinum combinations, with Gemcitabine sometimes reported to have fewer side effects- AKosimidis showed that a nonplatinum-containing regimen was equivalent to standard carboplatin/paclitaxel for the treatment of advanced disease.  The results of this study are also consistent with the recent South West Oncology Group (SWOG) and Eastern Cooperative Oncology Group (ECOG) studies presented at the American Society for Clinical Oncology (ASCO) over the past 2 years.@  Kosmidis (4). 

 

6.      Gene and angiogenic therapy is debated and investigated.  Tarceva and Iressa appear to benefit non-smokers and light former smokers with adenocarcinoma and its subtypes.   Initial studies indicate Avastin provides a modest benefit in survival though side effects are increased.

 

19.32 Stage 3 B Patients Managed Best by Chemotherapy and Radiation

NCI states, " Patients with stage IIIb non-small cell lung cancer (NSCLC) do not benefit from surgery alone and are best managed by initial chemotherapy, chemotherapy plus radiation therapy, or radiation therapy alone, depending on sites of tumor involvement and performance status. Most patients with excellent performance status should be considered for combined modality therapy. However, patients with malignant pleural effusion are rarely candidates for radiation therapy, and should generally be treated similarly to stage IV patients (see separate section of this summary on treatment of stage IV disease). Many randomized studies of unresectable patients with stage III NSCLC show that treatment with neoadjuvant or concurrent cisplatin-based chemotherapy and chest irradiation is associated with improved survival compared to treatment with radiation therapy alone.[1-5] A meta-analysis of patient data from 11 randomized clinical trials showed that cisplatin-based combinations plus radiation therapy resulted in 10% reduction in the risk of death compared with radiation therapy alone.[6]

Patients with stage IIIb disease  are frequently candidates for chest irradiation to palliate pulmonary symptoms (e.g., cough, shortness of breath, or local chest pain). "


lung cancer treatment, asbestos lung cancer, small cell lung cancer, lung cancer stage, early symptom of lung cancer
non small cell lung cancer, stage 3 lung cancer, sign of lung cancer, stage 3 lung cancer, cause of lung cancer
information on lung cancer, type of lung cancer, alternative lung cancer treatment, lung cancer survival rate
smoking and lung cancer, metastatic lung cancer, lung cancer prognosis, 
stage 3 asbestos lung cancer, , sign and symptom of lung cancer, lung cancer statistics
lung cancer fact, lung cancer survivor, stage 3 lung cancer, adenocarcinoma lung cancer, chemotherapy for lung cancer
squamous cell lung cancer, lung cancer prevention, lung cancer research, lung cancer surgery, stage 3A lung cancer
stage 3B lung cancer final stage, stage three lung cancer, lung cancer effects, lung cancer survival, lung cancer info
lung cancer diagnosis, large cell lung cancer, small cell lung cancer prognosis, early sign of lung cancer
life expectancy lung cancer, end stage lung cancer, lung cancer staging, advanced lung cancer, lung cancer x ray
asbestos cancer lung treatment, terminal lung cancer, history of lung cancer, lung cancer article.
dying of lung cancer, lung cancer treatment center, cancer lung lining, lung cancer stage 3, cancer and depression, lung cancer and depression,
 

Since stage 3B and 4 are treated essentially the same, please review our chapter on stage 4 treatment for additional information. stage 4 lung cancer treatment
or order our book.    

                      Lung Cancer and Mesothelioma

REVIEWS  
 
Quality Books "This book provides an invaluable resource for anyone who has or who is caring others with Mesothelioma or other Lung cancers. It provides a wealth of relevant and useful information on various types of lung cancers, medical trials, treatments and medications. This well researched and comprehensive book is quite unique on the subject. This book also contains a detailed discussion on the emotional burden of Lung Cancer upon the patient and their families and ways to manage it."
                    
 Lorraine Kember. Author of "Lean on Me - Cancer through a Carer's Eyes", "The very mention of the word Cancer, strikes fear into all of us.... From personal experience I know that knowledge is the key to providing a better "quality of life" for the cancer patient. Better understanding of the stages of the disease and of methods and medications available to treat the pain and symptoms caused by it, allow for the patient and those who care for them, to make informed decisions regarding their care. In this way, they are able to regain some control over their lives. Rarely does one find all the information they need in one book, however I believe Howard's well researched and comprehensive book "Lung Cancer & Mesothelioma", is quite unique. It provides a wealth of relevant and useful information including; how various types of cancer are formed, medical trials, available treatments and medications, insight and discussion regarding the emotional burden of cancer upon the patient and their families and ways by which to manage grief. I believe this book will provide an invaluable resource for anyone who has or who is caring for someone with cancer.

Order from the publisher www.xlibris.com or amazon.com